

In the Claims:

Please amend the claims as follows:

37. (Previously Added) A purified non-hamster antibody or portion thereof that binds to a polypeptide consisting of SEQ ID NO:2.

38. (Previously Added) The antibody or portion thereof of claim 37, wherein the antibody is monoclonal.

39. (Previously Added) The antibody or portion thereof of claim 37, wherein the antibody is polyclonal.

40. (Previously Added) The antibody or portion thereof of claim 38, wherein the antibody binds to the extracellular region of the polypeptide.

41. (Previously Added) The antibody or portion thereof of claim 38, wherein the antibody is a human, mouse, rat, guinea pig, rabbit, dog, cat, pig, goat, horse or cow antibody.

42. (Previously Added) The antibody or portion thereof of claim 38, wherein the antibody is a human, mouse or rat antibody.

43. (Previously Added) The antibody or portion thereof of claim 38, wherein the antibody is chimeric.

44. (Previously Added) The antibody or portion thereof of claim 38, wherein the antibody is humanized.

45. (Previously Added) The antibody or portion thereof of claim 38, wherein the antibody is a human antibody.

OK to enter
8/14/03 JWR

H1

SUB I

46. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 37 and a pharmaceutically acceptable carrier.

47. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 38 and a pharmaceutically acceptable carrier.

48. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 39 and a pharmaceutically acceptable carrier.

49. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 40 and a pharmaceutically acceptable carrier.

SUB I

50. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 41 and a pharmaceutically acceptable carrier.

51. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 42 and a pharmaceutically acceptable carrier.

52. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 43 and a pharmaceutically acceptable carrier.

53. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 44 and a pharmaceutically acceptable carrier.

54. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 45 and a pharmaceutically acceptable carrier.

55. (Previously Added) A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 46.

H₁
cont

56. (Previously Added) A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 47.

57. (Previously Added) A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 48.

58. (Previously Added) A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 49.

SUBI

59. (Previously Added) A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 50.

60. (Previously Added) A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 51.

61. (Previously Added) A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 52.

62. (Previously Added) A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 53.

H₁
cont

63. (Previously Added) A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 54.

64. (Previously Added) A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 46.

65. (Previously Added) A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 47.

Hi
cut
66. (Previously Added) A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 48.

67. (Previously Added) A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 49.

68. (Previously Added) A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 50.

69. (Previously Added) A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 51.

SUB I

70. (Previously Added) A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 52.

71. (Previously Added) A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 53.

72. (Previously Added) A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 54.

SUBI

73. (Previously Added) An isolated cell that produces the antibody of claim 38.

74. (Previously Added) An isolated cell that produces the antibody of claim 40.

75. (Previously Added) An isolated cell that produces the antibody of claim 41.

76. (Previously Added) An isolated cell that produces the antibody of claim 42.

77. (Previously Added) An isolated cell that produces the antibody of claim 43.

78. (Previously Added) An isolated cell that produces the antibody of claim 44.

79. (Previously Added) An isolated cell that produces the antibody of claim 45.

80. (Previously Added) A purified chimeric, humanized or human monoclonal antibody or a portion thereof that binds to a polypeptide consisting of SEQ ID NO:2.

H₁
cont

81. (Previously Added) The antibody or portion thereof of claim 80, wherein the antibody binds to the extracellular region of the polypeptide.

82. (Previously Added) The antibody or portion thereof of claim 80, wherein the antibody is chimeric.

83. (Previously Added) The antibody or portion thereof of claim 80, wherein the antibody is humanized.

84. (Previously Added) The antibody of claim 80, wherein the antibody is a human antibody.

SUB I

85. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 80 and a pharmaceutically acceptable carrier.

86. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 81 and a pharmaceutically acceptable carrier.

87. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 82 and a pharmaceutically acceptable carrier.

88. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 83 and a pharmaceutically acceptable carrier.

89. (Previously Added) A pharmaceutical composition comprising the antibody of claim 84 and a pharmaceutically acceptable carrier.

90. (Previously Added) A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 85.

91. (Previously Added) A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 86.

92. (Previously Added) A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 87.

93. (Previously Added) A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 88.

94. (Previously Added) A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 89.

95. (Previously Added) A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 85.

96. (Previously Added) A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 86.

97. (Previously Added) A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 87.

98. (Previously Added) A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 88.

99. (Previously Added) A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 89.

100. (Previously Added) An isolated cell that produces the antibody of claim 80.

101. (Previously Added) An isolated cell that produces the antibody of claim 81.

102. (Previously Added) An isolated cell that produces the antibody of claim 82.

103. (Previously Added) An isolated cell that produces the antibody of claim 83.

104. (Previously Added) An isolated hybridoma cell that produces the antibody of claim 84.

SUB I

105. (Previously Added) A process for producing a cell which secretes an antibody that binds to a polypeptide consisting of SEQ ID NO:2, comprising:

- i) immunizing a mammal with an immunogen selected from the group consisting of:
- a) an isolated polypeptide consisting of SEQ ID NO:2;
 - b) an isolated polypeptide comprising the extracellular region of SEQ ID NO:2;
 - c) an isolated homodimer molecule consisting of two polypeptide defined in a) or two polypeptides defined in b); and
 - d) a recombinant cell transfected with a DNA encoding a polypeptide consisting of SEQ ID NO:2, wherein the cell expresses the polypeptide;
- ii) obtaining from the mammal cells that secrete antibodies, or generating from cells of the mammal cell lines that secrete antibodies; and

iii) identifying from the cells obtained in ii) or from the cell lines generated in ii) a cell that secretes an antibody that binds to a polypeptide consisting of SEQ ID NO:2.

106. (Previously Added) The process of claim 105, wherein the antibody secreted by the cell identified in step iii) is a human antibody.

107. (Previously Added) The process of claim 105, wherein the cell identified in step iii) is a hybridoma cell.

108. (Previously Added) The process of claim 105, wherein the antibody secreted by the cell identified in step iii) binds to the extracellular region of the polypeptide consisting of SEQ ID NO:2.

SUB I

109. (Previously Added) The process of claim 105, wherein the mammal is a hamster.

110. (Previously Added) A process for producing an antibody that binds to a polypeptide consisting of SEQ ID NO:2, comprising providing a culture of the cell identified in claim 105, and collecting the antibody from the culture.

111. (Previously Added) A process for producing an antibody that binds to a polypeptide consisting of SEQ ID NO:2, comprising providing a culture of the cell identified in claim 106, and collecting the antibody from the culture.

112. (Previously Added) A process for producing an antibody that binds to a polypeptide consisting of SEQ ID NO:2, comprising providing a culture of the cell identified in claim 107, and collecting the antibody from the culture.

113. (Previously Added) A process for producing an antibody that binds to a polypeptide consisting of SEQ ID NO:2, comprising providing a culture of the cell identified in claim 108, and collecting the antibody from the culture.

H₁
cont

114. (Previously Added) A process for producing an antibody that binds to a polypeptide consisting of SEQ ID NO:2, comprising providing a culture of the cell identified in claim 109, and collecting the antibody from the culture.

115-139. (Canceled)

140. (Previously Added) A purified chimeric, humanized or human monoclonal antibody or a portion thereof that binds to a polypeptide consisting of SEQ ID NO:13.

141. (Previously Added) The antibody or portion thereof of claim 140, wherein the antibody binds to the extracellular region of the polypeptide.

142. (Previously Added) The antibody or portion thereof of claim 140, wherein the antibody is chimeric.

SUB I

143. (Previously Added) The antibody or portion thereof of claim 140, wherein the antibody is humanized.

144. (Previously Added) The antibody of claim 140, wherein the antibody is a human antibody.

145. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 140 and a pharmaceutically acceptable carrier.

146. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 141 and a pharmaceutically acceptable carrier.

147. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 142 and a pharmaceutically acceptable carrier.

148. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 143 and a pharmaceutically acceptable carrier.

149. (Previously Added) A pharmaceutical composition comprising the antibody of claim 144 and a pharmaceutically acceptable carrier.

150. (Previously Added) An isolated cell that produces the antibody of claim 140.

151. (Previously Added) An isolated cell that produces the antibody of claim 141.

152. (Previously Added) An isolated cell that produces the antibody of claim 142.

153. (Previously Added) An isolated cell that produces the antibody of claim 143.

154. (Previously Added) An isolated hybridoma cell that produces the antibody of claim 144.

155-164. (Canceled)

165. (Previously Added) A purified non-hamster antibody or portion thereof that binds to a polypeptide consisting of SEQ ID NO:14.

166. (Previously Added) The antibody or portion thereof of claim 165, wherein the antibody is monoclonal.

167. (Previously Added) The antibody or portion thereof of claim 165, wherein the antibody is polyclonal.

509 I 1

H1
cont

168. (Previously Added) The antibody or portion thereof of claim 166, wherein the antibody binds to the extracellular region of the polypeptide.

169. (Previously Added) The antibody or portion thereof of claim 166, wherein the antibody is a human, rat, guinea pig, rabbit, dog, cat, pig, goat, horse or cow antibody.

170. (Previously Added) The antibody or portion thereof of claim 166, wherein the antibody is a human, rat or guinea pig antibody.

171. (Previously Added) The antibody or portion thereof of claim 166, wherein the antibody is chimeric.

172. (Previously Added) The antibody or portion thereof of claim 166, wherein the antibody is humanized.

173. (Previously Added) The antibody or portion thereof of claim 166, wherein the antibody is a human antibody.

SUBI

174. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 165 and a pharmaceutically acceptable carrier.

175. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 166 and a pharmaceutically acceptable carrier.

176. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 167 and a pharmaceutically acceptable carrier.

177. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 168 and a pharmaceutically acceptable carrier.

178. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 169 and a pharmaceutically acceptable carrier.

179. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 170 and a pharmaceutically acceptable carrier.

180. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 171 and a pharmaceutically acceptable carrier.

181. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 172 and a pharmaceutically acceptable carrier.

182. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 173 and a pharmaceutically acceptable carrier.

183. (Previously Added) An isolated cell that produces the antibody of claim 166.

184. (Previously Added) An isolated cell that produces the antibody of claim 168.

185. (Previously Added) An isolated cell that produces the antibody of claim 169.

186. (Previously Added) An isolated cell that produces the antibody of claim 170.

187. (Previously Added) An isolated cell that produces the antibody of claim 171.

188. (Previously Added) An isolated cell that produces the antibody of claim 172.

189. (Previously Added) An isolated cell that produces the antibody of claim 173.

H.
cont

509 I1

190. (Previously Added) A purified chimeric, humanized or human monoclonal antibody or a portion thereof that binds to a polypeptide consisting of SEQ ID NO:14.

191. (Previously Added) The antibody or portion thereof of claim 190, wherein the antibody binds to the extracellular region of the polypeptide.

192. (Previously Added) The antibody or portion thereof of claim 190, wherein the antibody is chimeric.

193. (Previously Added) The antibody or portion thereof of claim 190, wherein the antibody is humanized.

194. (Previously Added) The antibody of claim 190, wherein the antibody is a human antibody.

195. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 190 and a pharmaceutically acceptable carrier.

196. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 191 and a pharmaceutically acceptable carrier.

197. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 192 and a pharmaceutically acceptable carrier.

198. (Previously Added) A pharmaceutical composition comprising the antibody or portion thereof of claim 193 and a pharmaceutically acceptable carrier.

199. (Previously Added) A pharmaceutical composition comprising the antibody of claim 194 and a pharmaceutically acceptable carrier.

H
cont

Sub I

200. (Previously Added) An isolated cell that produces the antibody of claim 190.

201. (Previously Added) An isolated cell that produces the antibody of claim 191.

202. (Previously Added) An isolated cell that produces the antibody of claim 192.

203. (Previously Added) An isolated cell that produces the antibody of claim 193.

204. (Previously Added) An isolated hybridoma cell that produces the antibody of claim 194.

205. (Previously Added) A process for producing a cell which secretes an antibody that binds to a polypeptide consisting of SEQ ID NO:14, comprising:

i) immunizing a mammal with an immunogen selected from the group consisting of:

a) an isolated polypeptide consisting of SEQ ID NO:14;

b) an isolated polypeptide comprising the extracellular region of SEQ ID NO:14;

c) an isolated homodimer molecule consisting of two polypeptide defined in a) or two polypeptides defined in b); and

d) a recombinant cell transfected with a DNA encoding a polypeptide consisting of SEQ ID NO:14, wherein the cell expresses the polypeptide;

ii) obtaining from the mammal cells that secrete antibodies, or generating from cells of the mammal cell lines that secrete antibodies; and

iii) identifying from the cells obtained in ii) or from the cell lines generated in ii) a cell that secretes an antibody that binds to a polypeptide consisting of SEQ ID NO:14.

206. (Previously Added) The process of claim 205, wherein the antibody secreted by the cell identified in step iii) is a human antibody.

207. (Previously Added) The process of claim 205, wherein the cell identified in step iii) is a hybridoma cell.

208. (Previously Added) The process of claim 205, wherein the antibody secreted by the cell identified in step iii) binds to the extracellular region of the polypeptide consisting of SEQ ID NO:14.

209. (Previously Added) The process of claim 205, wherein the mammal is a hamster.

210. (Previously Added) A process for producing an antibody that binds to a polypeptide consisting of SEQ ID NO:14, comprising providing a culture of the cell identified in claim 205, and collecting the antibody from the culture.

SUB I

211. (Previously Added) A process for producing an antibody that binds to a polypeptide consisting of SEQ ID NO:14, comprising providing a culture of the cell identified in claim 206, and collecting the antibody from the culture.

212. (Previously Added) A process for producing an antibody that binds to a polypeptide consisting of SEQ ID NO:14, comprising providing a culture of the cell identified in claim 207, and collecting the antibody from the culture.

213. (Previously Added) A process for producing an antibody that binds to a polypeptide consisting of SEQ ID NO:14, comprising providing a culture of the cell identified in claim 208, and collecting the antibody from the culture.

214. (Previously Added) A process for producing an antibody that binds to a polypeptide consisting of SEQ ID NO:14, comprising providing a culture of the cell identified in claim 209, and collecting the antibody from the culture.